… In order to increase the understanding to the entire spectrum of EGFR mutations, we … To
evaluate the effectiveness of EGFR TKI treatment in patients with uncommon EGFR mutation …

… gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS in patients
with untreated NSCLC EGFR mutation … the intracranial efficacy and safety of gefitinib plus …

… effective advantage over gefitinib in all three groups, especially the del19 subgroup. However,
the clinical efficacy and prognosis of the del19 and L858R mutations are still controversial…

… : Although EGFR-TKI alone has been a standard first-line treatment for pts with advanced
NSCLC with EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP. …

… -TKIs in the treatment of NSCLC patients according to different EGFR genotypes. … different
EGFR mutations treated by second-line TKIs were retrospectively reviewed. The efficacy was …

… gene were eligible for this study, patients with other EGFR mutations were excluded from …
study, the effectiveness of the combination of bevacizumab and gefitinib for patients with EGFR …

… by EGFR mutations warrants the … efficacy of osimertinib combined with gefitinib were
assessed in an ongoing phase I/II study (NCT03122717 ) as a first-line treatment for EGFR-mutated …

… EGFR-TKI for their metastatic EGFR-mutated NSCLC. For the current analysis, we prospectively
evaluated the efficacy … chemotherapy and first-generation EGFR-TKI under a Boehringer …

… that osimertinib is the most efficacious and safest EGFR-TKI. … EGFR-TKIs for their patient’s
individual clinical characteristics. … mutations discovered to be associated with EGFR mutation …

… of the T790M and C797S mutations demonstrated some efficacy in our patient, although the
… the efficacy of combination EGFR TKIs can be taken beyond a novel in vitro observation. …